...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma
【24h】

Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma

机译：术前Lanreotide治疗可改善垂体浸润性腺瘤浸润引起的肢端肥大症患者的结局

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To investigate whether 3 months' preoperative treatment with lanreotide improved outcome in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma. METHODS: After baseline evaluation, untreated patients were randomized to undergo direct trans-sphenoidal surgery or lanreotide treatment (30 mg via intramuscular injection every 2 weeks, increased to 30 mg/week at week 8 if growth hormone nadir > 2.5 μg/l), for 3 months prior to surgery. Tumour shrinkage following lanreotide treatment was analysed. Cure was evaluated at 3 months postsurgery by measuring growth hormone and insulinlike growth factor-1 (IGF-1) levels. RESULTS: Preoperative lanreotide treatment significantly reduced mean tumour size. Growth hormone and IGF-1 levels were lower in the pretreatment group than in the direct surgery group at 3 months postsurgery. According to combined growth hormone and IGF-1 levels, significantly more patients were cured by trans-sphenoidal surgery in the pretreatment group compared with the direct surgery group (11 of 24 and five of 25 patients, respectively). CONCLUSIONS: Lanreotide treatment for 3 months before trans-sphenoidal surgery effectively reduced tumour size, and improved surgical cure rate, in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma.
机译：目的：探讨兰瑞肽的3个月术前治疗是否能改善新诊断的侵袭性垂体大腺瘤引起的肢端肥大症患者的预后。方法：基线评估后，未经治疗的患者随机接受直接经蝶骨手术或兰瑞肽治疗（每2周通过肌肉注射30 mg，如果生长激素最低点> 2.5μg/ l，则在第8周增加至30 mg /周），手术前3个月。分析了兰瑞肽治疗后的肿瘤缩小。通过测量生长激素和类胰岛素生长因子-1（IGF-1）的水平评估术后3个月的治愈情况。结果：术前兰瑞肽治疗显着降低了平均肿瘤大小。术后3个月，预处理组的生长激素和IGF-1水平低于直接手术组。根据生长激素和IGF-1的联合水平，与直接手术组相比，预处理组经蝶窦手术治愈的患者明显多于直接手术组（分别为24例中的11例和25例中的5例）。结论：经蝶窦手术前3个月的兰瑞肽治疗可有效减少新诊断为侵袭性垂体大腺瘤的肢端肥大症患者的肿瘤大小，并提高手术治愈率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号